Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.74 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.61 |
| ▸ | ACHE | P22303 | 3/20 | 0.58 |
| ▸ | RAD52 | P43351 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | PAM | P19021 | 2/20 | 0.56 |
| ▸ | FABP3 | P05413 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.54 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.53 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.53 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.53 |
| ▸ | NAAA | Q02083 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL200400 | 1.00 | DGKA (0.74) | DGKAADRA2AADRA1AMAPTBLM | |
| SCHEMBL198091 | 1.00 | DGKA (0.74) | DGKAADRA2AADRA1AMAPTBLM | |
| SCHEMBL8385105 | 1.00 | DGKA (0.74) | DGKAADRA2AADRA1AMAPTBLM | |
| SCHEMBL8383254 | 1.00 | DGKA (0.74) | DGKAADRA2AADRA1AMAPTBLM | |
| SCHEMBL153530 | 1.00 | DGKA (0.74) | DGKAADRA2AADRA1AMAPTBLM | |
| SCHEMBL8385120 | 1.00 | DGKA (0.74) | DGKAADRA2AADRA1AMAPTBLM | |
| SCHEMBL8385098 | 1.00 | DGKA (0.74) | DGKAADRA2AADRA1AMAPTBLM | |
| SCHEMBL6829812 | 1.00 | DGKA (0.74) | DGKAADRA2AADRA1AMAPTBLM | |
| SCHEMBL8855865 | 1.00 | DGKA (0.74) | DGKAADRA2AADRA1AMAPTBLM | |
| SCHEMBL8382713 | 1.00 | DGKA (0.74) | DGKAADRA2AADRA1AMAPTBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115140-A1 | COMPOSITIONS FOR ENHANCED MUCOSAL PENETRATION | SHIN NIPPON BIOMEDICAL LABORATORIES LTD (JP) | 2026-04-30 | — | — | US | claimed |
| EP-4719476-A1 | COMPOSITIONS FOR ENHANCED MUCOSAL PENETRATION | Shin Nippon Biomedical Laboratories, Ltd. (JP) | 2026-04-08 | — | — | EP | claimed |
| US-12292445-B2 | Methods of selecting subjects for treatment with metabolomic modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-05-06 | — | — | US | claimed |
| WO-2024246607-A1 | COMPOSITIONS FOR ENHANCED MUCOSAL PENETRATION | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) | 2024-12-05 | — | — | WO | claimed |
| EP-4226918-A1 | PHARMACEUTICAL SINGLE DOSAGE FORM FOR ORAL DELIVERY OF PEPTIDES | Majewski, Filip (PL) | 2023-08-16 | — | — | EP | claimed |
| US-20210407677-A1 | FATTY ACID AND KREBS CYCLE METABOLOMIC MEASURES FOR TREATMENT OF HEAD INJURY | NORTHWESTERN UNIVERSITY (US) | 2021-12-30 | — | — | US | claimed |
| US-20210364526-A1 | METHODS OF SELECTING SUBJECTS FOR TREATMENT WITH METABOLOMIC MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-11-25 | — | — | US | claimed |
| US-20160339081-A1 | Peptide Pharmaceutical for Oral Delivery | UNIGENE LABORATORIES INC. | 2016-11-24 | — | — | US | claimed |
| US-20100286073-A1 | COMPOUNDS AND METHODS FOR PHARMACEUTICAL USE | GENERICS (UK) LIMITED (GB) | 2010-11-11 | — | — | US | claimed |
| EP-2205229-A1 | COMPOUNDS AND METHODS FOR PHARMACEUTICAL USE | Mintails Limited (CY) | 2010-07-14 | — | — | EP | claimed |
| WO-1994025053-A1 | ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF | SCOTGEN BIOPHARMACEUTICALS, INC. (US) | 1994-11-10 | — | — | WO | claimed |
| EP-0206947-B1 | PHARMACEUTICAL COMPOSITION CONTAINING CHOLINE ESTER SALTS FOR ENHANCING GASTROINTESTINAL TRACT ABSORPTION | MERCK & CO. INC. (US) | 1992-04-15 | — | — | EP | claimed |
| EP-0214898-B1 | CHOLINE ESTERS AS ABSORPTION-ENHANCING AGENTS FOR DRUG DELIVERY THROUGH MUCOUS MEMBRANES OF THE NASAL, BUCCAL, SUBLINGUAL AND VAGINAL CAVITIES | MERCK & CO. INC. (US) | 1992-03-11 | — | — | EP | claimed |
| US-4973579-A | VIRICIDES | MERCK & CO., INC. (US) | 1990-11-27 | — | — | US | claimed |
| US-4963556-A | ANTIVIRAL AGENTS | MERCK & CO., INC. (US) | 1990-10-16 | — | — | US | claimed |
| US-4835138-A | Choline esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities | MERCK & CO., INC. (US) | 1989-05-30 | — | — | US | claimed |
| US-4822773-A | Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts | MERCK & CO., INC. (US) | 1989-04-18 | — | — | US | claimed |
| US-4729989-A | Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts | MERCK & CO., INC. (US) | 1988-03-08 | — | — | US | claimed |
| US-4692441-A | B-LACTAM ANTIBIOTICS | MERCK & CO., INC. (US) | 1987-09-08 | — | — | US | claimed |
| EP-0214898-A2 | Choline esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities | MERCK & CO. INC. (US) | 1987-03-18 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115140-A1 | COMPOSITIONS FOR ENHANCED MUCOSAL PENETRATION | SLC10A2, SLC5A7, SLC18A3 | DGKA 3663/4885ADRA2A 619/4885ADRA1A 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.